

Synthesis of pyrazole encompassing 2-pyridone derivatives as antibacterial agents

Nisheeth C. Desai ^{*}, Kiran M. Rajpara, Vivek V. Joshi

Division of Medicinal Chemistry, Department of Chemistry, (DST-FIST Sponsored Department) Mahatma Gandhi Campus, Maharaja Krishnakumarsinhji Bhavnagar University, Bhavnagar 364 002, India

ARTICLE INFO

Article history:

Received 16 January 2013

Revised 6 February 2013

Accepted 15 February 2013

Available online 26 February 2013

Keywords:

Pyrazole

2-Pyridone

Antibacterial activity

Cytotoxicity

ABSTRACT

A series of novel compounds 6-amino-1-((1,3-diphenyl-1H-pyrazole-4-yl)methyleneamino)-4-(aryl)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitriles (**4a–t**) were synthesized and characterized by IR, ¹H NMR, ¹³C NMR and mass spectral data. These compounds were screened for their in vitro antibacterial activity against *Staphylococcus aureus*, *Streptococcus pyogenes* (Gram positive), *Escherichia coli*, *Pseudomonas aeruginosa* (Gram negative) by serial broth dilution and cytotoxic activity (NIH 3T3 & HeLa) by MTT assay. The results indicated that compounds **4g**, **4i**, **4m**, **4o**, **4r** and **4t** exhibit potent antibacterial activity against bacterial strains at non-cytotoxic concentrations.

© 2013 Elsevier Ltd. All rights reserved.

Since resistance of pathogenic bacteria towards available antibiotics is rapidly becoming a major worldwide problem, the design of new compounds to deal with resistant bacteria has become one of the most important areas of antibacterial research today.¹ Despite the development of several new antibacterial agents, their clinical value is limited to treating an increasing array of life-threatening systemic infections because of their relatively high risk of toxicity, emergence of drug resistant strains, pharmacokinetic differences, and/or insufficiencies in their activity.

Pyridone and their derivatives play an essential role in several biological processes and have considerable chemical and pharmacological importance.^{2–4} 2-Pyridones represent a unique class of pharmacophores, which are observed in various therapeutic agents⁵ and antibiotics.⁶ In recent years, 2-pyridones have captivated much importance as these compounds have been found to exhibit several biological activities, such as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs),⁷ antifungals,⁸ sedatives⁹ and cardiotonic agents.^{10–12} Moreover, 2-pyridones are a class of recently discovered potent antibacterial agents that are of particular interest due to their in vitro and in vivo antibacterial potencies against the bacterial type II DNA topoisomerases, which includes two highly homologous enzymes DNA gyrase and topoisomerase IV.¹³ Furthermore, pyrazoles occupy a distinct place in heterocyclic chemistry and represent a key motif in medicinal chemistry due to their capability to exhibit an array of bioactivities such as antimicrobial,^{14–16} anticancer,¹⁷ anti-inflammatory,¹⁸ antidepressant,¹⁹ anticonvulsant,²⁰ antipyretic²¹ and selective enzyme inhibitory

activities.²² Recently, we have reported pyrazole containing compounds as antibacterial agents (NCD_{1–17}) (Fig. 1).²³ Recognizing these facts and in continuation of our previous work^{24,25} to look for new antibacterial agents with possible novel mechanisms of action, it was thought worthwhile to synthesize some new congeners of 2-pyridones by incorporating 2-pyridones and pyrazoles in a single molecular framework.

The quest for synthesis of 6-amino-1-((1,3-diphenyl-1H-pyrazole-4-yl)methyleneamino)-4-(aryl)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitriles (**4a–t**) was accomplished in two steps as outlined in Scheme 1. In the first step, 1,3-diphenylpyrazole-4-carboxaldehyde (**1**), prepared according to previously published methods²⁶ was condensed with cyanoacetic acid hydrazide using 1,4-dioxane as a solvent to yield the intermediate 2-cyano-N-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)acetohydrazide (**2**).²⁷ In the second step, the intermediate **2** was further reacted with (2-arylidene)malononitriles (**3a–t**) in the presence of catalytic amount of piperidine utilizing ethanol (95%) as a solvent to yield the desired products 6-amino-1-((1,3-diphenyl-1H-pyrazole-4-yl)methyleneamino)-4-(aryl)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitriles (**4a–t**).²⁸ The yields of the products were obtained in the range of 54–65%. Designed series of molecules **4a–t** were characterized by IR, ¹H NMR, ¹³C NMR, and mass spectrometry techniques before evaluating for in vitro antibacterial and cytotoxicity essays.

IR spectrum of compound **4o** showed stretching band of carbonyl group at 1684 cm^{−1} and absorption bands of NH₂ group at 3439 and 3448 cm^{−1}. Strong intense absorption bands were observed at 2210 and 2214 cm^{−1} due to stretching vibration of –C≡N groups. In ¹H NMR spectra of **4o**, characteristic signal of

^{*} Corresponding author. Tel./fax: +91 278 2439852.

E-mail address: dnisheeth@rediffmail.com (N.C. Desai).




Figure 1. Structural similarity between newly synthesized compounds and previously synthesized compounds.

primary amine showed a broad singlet at $\delta = 5.93$ ppm which is exchangeable with D_2O . The aromatic and $CH=N$ protons appeared at $\delta = 7.29$ – 8.50 ppm. The ^{13}C NMR spectrum of compound **4o** displayed characteristic signal of carbonyl carbon at $\delta = 171.2$ ppm. Carbons of $-C\equiv N$ group showed a chemical shift at $\delta = 115.6$ ppm. Carbon of nitrophenyl ring showed a chemical shift at $\delta = 148.2$ ppm. The mass spectrum revealed a molecular ion peak at $m/z = 526$. In mass spectra, molecular ion peak is in agreement with proposed molecular weight and elemental analysis.

A plausible mechanism for the formation of compounds (**4a–t**) is suggested in Scheme 2. Firstly, the Michael addition of Schiff base cyanoacetic hydrazide **a** to Knoevenagel product **b** yielded the intermediate **c**, which further underwent intramolecular nucleophilic attack on cyano carbon followed by annulation to give intermediate **e**. The compound **e** was converted to final compound by intramolecular electron transfer to nitrogen atom.


All the newly synthesized compounds (**4a–t**) were initially screened for their in vitro antibacterial activity against Gram positive bacteria (*Staphylococcus aureus* (MTCC-96), *Streptococcus pyogenes* (MTCC-442)) and Gram negative bacteria (*Escherichia coli* (MTCC-443), *Pseudomonas aeruginosa* (MTCC-1688)) using conventional broth-dilution method.²⁹ The MIC (minimum inhibitory concentration) values were determined by using ciprofloxacin as reference drug. The results of antibacterial studies of newly synthesized compounds revealed that these compounds exhibited significant antibacterial activity. From antibacterial activity data (Table 1), it was observed that compounds **4f** (2-Cl), **4g** (2-F), **4i** (4-F), **4m** (2- NO_2), **4o** (4- NO_2), **4p** (2-Br), **4r** (4-Br) and **4t** (4- CF_3) were most active compounds. Compound **4m** (2- NO_2) exhibited inhibition at MIC = 25 $\mu g/mL$ and compounds **4i** (4-F) and **4o** (4-

NO_2) displayed strong inhibition action at MIC = 12.5 $\mu g/mL$ against *E. coli*. Compounds **4i** (4-F) and **4o** (4- NO_2) showed appreciable activity at MIC = 25 $\mu g/mL$ against *P. aeruginosa*. Compounds **4g** (2-F), **4m** (2- NO_2) and **4t** (4- CF_3) exhibited significant potential at MIC = 25 $\mu g/mL$ while compounds **4i** (4-F), **4p** (2-Br) and **4r** (4-Br) exerted highest inhibition at MIC = 12.5 $\mu g/mL$ against *S. aureus*. Compound **4g** (2-F) indicated good inhibition at MIC = 25 $\mu g/mL$ and compounds **4f** (4-Cl) and **4o** (4- NO_2) showed remarkable activity at MIC = 12.5 $\mu g/mL$ against *S. pyogenes*.


As shown in our results, some analogues of this series were found to have more potency than the standard drug ciprofloxacin while some of them have comparable potency. The antimicrobial activity was considerably affected by substitution pattern on the phenyl ring and the most active compounds contained an electron withdrawing substituent at *ortho* and *para* positions of the phenyl ring. The role of electron withdrawing group in improving antimicrobial activity is very well supported by previous studies.^{30,31} Compounds **4g**, **4i**, **4m**, **4o**, **4r** and **4t** bearing F, Cl, NO_2 , Br, and CF_3 groups were most potent. Thus, compounds bearing substituents at 2- or 4-position of the terminal benzene ring of 2-pyridone part were found to have higher potency than compounds bearing groups at 3-position or at both. Moreover all active compounds were effective against Gram negative bacterial strain *S. aureus*. Rest of the compounds bearing these substituents at 3-position showed moderate activity with respect to standard drug against the test strains.

All the newly synthesized compounds **4a–t** were tested for cytotoxic activity on Mouse embryonic fibroblasts cell line (NIH 3T3) and human cervical cancer cell line (HeLa) using MTT colorimetric assay.³² The IC_{50} values obtained for these compounds are shown in Table 2. Pyrazole analogues **4g**, **4i**, **4m**, **4r** and **4t** showed no toxicity at concentration of 200 $\mu g/mL$ ($IC_{50} > 200 \mu g/mL$), while other compounds showed moderate toxicity against NIH 3T3 cells. Moreover, none of the derivatives showed cytotoxicity against HeLa cells ($IC_{50} > 200 \mu g/mL$).

In conclusion, our attempts at exploring pyrazole based 2-pyridone derivatives have unexpectedly led to the identification of a novel chemotype with substantial antibacterial activity against various bacterial strains. Among the newly synthesized compounds **4a–t**, analogues **4g** (2-F), **4i** (4-F), **4m** (2- NO_2), **4o** (4- NO_2), **4r** (4-Br) and **4t** (4- CF_3) showed the highest inhibition against nearly all of the tested bacteria, superior to the reference drugs, and displayed antibacterial activity at non-cytotoxic concentrations. Our preliminary results suggest that the mechanism of action may be distinct from that of known antibacterial agents.



Scheme 1. Synthesis of title compounds **4a–t**.



Scheme 2. Plausible mechanistic pathway for the synthesis of compounds **4a–t**.

Table 1
 Results of antibacterial screening of compounds **4a–t**

Entry	–R	Minimum inhibitory concentration (MIC) in $\mu\text{g/mL} \pm \text{SD}$			
		<i>E. coli</i> MTCC 443	<i>P. aeruginosa</i> MTCC 1688	<i>S. aureus</i> MTCC 96	<i>S. pyogenes</i> MTCC 442
4a	–H	250 \pm 3.05	500 \pm 1.00	500 \pm 4.04 ^c	500 \pm 3.46 ^c
4b	–2-OH	500 \pm 2.64 ^c	500 \pm 1.00 ^b	500 \pm 3.21	250 \pm 3.60 ^b
4c	–4-OH	500 \pm 3.21	500 \pm 2.88	500 \pm 2.05 ^b	500 \pm 2.05
4d	–2-Cl	100 \pm 1.60 ^b	100 \pm 2.04 ^b	100 \pm 3.05	100 \pm 3.21 ^c
4e	–3-Cl	50 \pm 3.61 ^c	250 \pm 4.04	500 \pm 1.16 ^c	100 \pm 3.21
4f	–4-Cl	500 \pm 3.60	500 \pm 1.60 ^b	100 \pm 1.05 ^a	12.5 \pm 4.16 ^o
4g	–2-F	250 \pm 1.20 ^b	50 \pm 3.60 ^c	25 \pm 2.04 ^c	25 \pm 1.92 ^c
4h	–3-F	100 \pm 1.78 ^c	50 \pm 2.21 ^b	50 \pm 4.16	50 \pm 3.78 ^b
4i	–4-F	12.5 \pm 3.78 ^c	25 \pm 3.78	12.5 \pm 2.04 ^b	100 \pm 3.46
4j	–4-CH ₃	500 \pm 2.44 ^c	250 \pm 1.21 ^c	500 \pm 4.16	250 \pm 1.78
4k	–4-OCH ₃	500 \pm 4.40	500 \pm 3.26	500 \pm 3.78 ^b	250 \pm 4.61 ^c
4l	–3,4,5-(OCH ₃) ₃	500 \pm 5.19 ^c	250 \pm 1.04 ^c	500 \pm 4.60 ^c	250 \pm 3.78 ^c
4m	–2-NO ₂	25 \pm 1.60 ^a	100 \pm 3.78 ^c	25 \pm 2.64	250 \pm 2.64 ^b
4n	–3-NO ₂	100 \pm 1.52 ^c	100 \pm 2.04 ^b	250 \pm 4.04 ^c	50 \pm 2.05 ^a
4o	–4-NO ₂	12.5 \pm 3.60	25 \pm 1.16 ^c	50 \pm 4.50 ^a	12.5 \pm 3.60 ^c
4p	–2-Br	100 \pm 2.52	250 \pm 2.98 ^a	12.5 \pm 1.86 ^b	250 \pm 2.84 ^c
4q	–3-Br	100 \pm 1.24 ^a	250 \pm 2.16 ^c	250 \pm 2.48 ^c	500 \pm 2.48 ^a
4r	–4-Br	500 \pm 2.14 ^c	100 \pm 1.28	12.5 \pm 2.28	100 \pm 3.64 ^c
4s	–2-CF ₃	100 \pm 1.38	250 \pm 1.84 ^c	100 \pm 1.34 ^a	250 \pm 1.52
4t	–4-CF ₃	250 \pm 3.46 ^c	25 \pm 1.24 ^c	25 \pm 1.68 ^c	250 \pm 2.10 ^c
Ciprofloxacin		25 \pm 2.05	25 \pm 1.0	50 \pm 1.52	50 \pm 2.06

$\pm \text{SD}$ = standard deviation.

^a $P < 0.001$ extremely significant.

^b $P < 0.01$ moderately significant.

^c $P < 0.05$ significant. All values are presented as mean of 6 experiments ($n = 6$). All significant differences are considered from control value 0.00.

Structure–activity relationship studies have led to identification of positions of pharmacophores on the scaffold for additional structural modifications. These modifications would allow the introduction of probes designed to examine cognate binding partners and molecular targets, at the same time not significantly compromising antibacterial potency.

Acknowledgment

We would like to express our sincere gratitude to the Department of Chemistry, (DST-FIST Sponsored), Mahatma Gandhi Campus, Maharaja Krishnakumarsinhji Bhavnagar University, Bhavnagar for providing research and library facilities.

Table 2
Cytotoxic activity of compounds **4a–t** against NIH 3T3 and HeLa cell line

Entry	Cytotoxicity (IC ₅₀)(μg/mL) ^a	
	NIH 3T3 ^b	HeLa ^c
4a	180 ± 2.4	>200
4b	162 ± 4.8	>200
4c	110 ± 4.4	>200
4d	84 ± 2.4	>200
4e	52 ± 1.2	>200
4f	64 ± 3	>200
4g	>200	>200
4h	154 ± 3.2	>200
4i	>200	>200
4j	98 ± 2.6	>200
4k	50 ± 1.4	>200
4l	64 ± 2.4	>200
4m	>200	>200
4n	124 ± 1.8	>200
4o	84 ± 3.6	>200
4p	174 ± 2.8	>200
4q	42 ± 3.2	>200
4r	>200	>200
4s	56 ± 2.6	>200
4t	>200	>200

The values represent mean ± SD.

^a IC₅₀ is the concentration required to inhibit 50% of cell growth.

^b NIH 3T3: Mouse embryonic fibroblasts cell line.

^c HeLa: Human cervical cancer cell line.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmcl.2013.02.077>.

References and notes

- Grare, M.; Mourer, M.; Fontanay, S.; Regnouf-de-Vains, J. B.; Finance, C.; Duval, R. E. *J. Antimicrob. Chemother.* **2007**, *60*, 575.
- Choi, W.-B.; Houpi, I. N.; Churchill, H. R. O.; Molina, A.; Lynch, J. E.; Volante, R. P.; Reider, P. J.; King, A. O. *Tetrahedron Lett.* **1995**, *36*, 4571.
- Bhupathy, M.; Conlon, D. A.; Wells, K. M.; Nelson, J. R.; Reider, P. J.; Rossen, K.; Sager, J. W.; Volante, R. P.; Dorsey, B. D.; Hoffman, J. M.; Joseph, S. A.; McDaniel, S. L. *J. Heterocycl. Chem.* **1995**, *32*, 1283.
- Kappe, C. O.; Kappe, T. *Monatsh. Chem.* **1989**, *120*, 1095.
- Saiki, A. Y.; Shen, L. L.; Chen, C. M.; Baranowski, J.; Lerner, C. G. *Antimicrob. Agents Chemother.* **1999**, *43*, 1574.
- Brickner, S. *Chem. Ind. (London)* **1997**, 131.
- Goldman, M. E.; Nunberg, J. H.; O'Brien, J. A.; Quintero, J. C.; Schleif, W. A.; Freund, K. F.; Gaul, S. L.; Saari, W. S.; Wai, J. S.; Hoffman, J. M., et al. *Proc. Natl. Acad. Sci. U.S.A.* **1991**, *88*, 6863.
- Gupta, A. K.; Plott, T. *Int. J. Dermatol.* **2004**, *43*, 3.
- Collins, I.; Moyes, C.; Davey, W. B.; Rowley, M.; Bromidge, F. A.; Quirk, K.; Attack, J. R.; McKernan, R. M.; Thompson, S. A.; Wafford, K.; Dawson, G. R.; Pike, A.; Sohal, B.; Tsou, N. N.; Ball, R. G.; Castro, J. L. *J. Med. Chem.* **1987**, *2002*, 45.
- Endoh, M.; Hori, M. *Expert Opin. Pharmacother.* **2006**, *7*, 2179.
- Robert, N.; Verrier, C.; Hoarau, C.; Celanire, S.; Marsais, F. *ARKIVOC* **2008**, *7*, 92.
- Lo Presti, E.; Boggia, R.; Feltrin, A.; Menozzi, G.; Dorigo, P.; Mosti, L. *Farmaco* **1999**, *54*, 465.
- Li, Q.; Mitscher, L. A.; Shen, L. L. *Med. Res. Rev.* **2000**, *20*, 231.
- Sullivan, T. J.; Truglio, J. J.; Boyne, M. E.; Novichenok, P.; Zhang, X.; Stratton, C. F.; Li, H.-J.; Kaur, T.; Amin, A.; Johnson, F.; Slayden, R. A.; Kisker, C.; Tonge, P. J. *ACS Chem. Biol.* **2006**, *1*, 43.
- Gilbert, A. M.; Failli, A.; Shumsky, J.; Yang, Y.; Severin, A.; Singh, G.; Hu, W.; Keeney, D.; Petersen, P. J.; Katz, A. H. *J. Med. Chem.* **2006**, *49*, 6027.
- Isloor, A. M.; Kalluraya, B.; Shetty, P. *Eur. J. Med. Chem.* **2009**, *44*, 3784.
- Magedov, I. V.; Manpadi, M.; Slambrouck, S. V.; Steelant, W. F.; Rozhkova, E.; Przheval'skii, N. M.; Rogelj, S.; Kornienko, A. *J. Med. Chem.* **2007**, *50*, 5183.
- Szabó, G.; Fischer, J.; Kis-Varga, A.; Gyires, K. *J. Med. Chem.* **2007**, *51*, 142.
- Rajendra Prasad, Y.; Lakshmana Rao, A.; Prasanna, L.; Murali, K.; Ravi Kumar, P. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 5030.
- Ozdemir, Z.; Kandilci, H. B.; Gumusel, B.; Calis, U.; Bilgin, A. A. *Eur. J. Med. Chem.* **2007**, *42*, 373.
- Şener, A.; Kasim Şener, M.; Bildmci, I.; Kasimogullari, R.; Akçamur, Y. *J. Heterocycl. Chem.* **2002**, *39*, 869.
- Wachter, G. A.; Hartmann, R. W.; Sergejew, T.; Grun, G. L.; Ledergerber, D. *J. Med. Chem.* **1996**, *39*, 834.
- Desai, N. C.; Joshi, V. V.; Rajpara, K. M.; Vaghani, H. V.; Satodiya, H. M. *J. Fluorine Chem.* **2012**, *142*, 67.
- Desai, N. C.; Rajpara, K. M.; Joshi, V. V.; Vaghani, H. V.; Satodiya, H. M. *Anti Infect. Agents* **2012**, *10*, 75.
- Desai, N. C.; Rajpara, K. M.; Joshi, V. V.; Vaghani, H. V.; Satodiya, H. M. *Med. Chem. Res.* **2013**, *22*, 1172.
- Prakash, O.; Pannu, K.; Naithani, R.; Kaur, H. *Synth. Commun.* **2006**, *36*, 3479.
- Synthesis of 2-cyano-N-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)acetohydrazide (**2**): A mixture containing 1,3-diphenylpyrazole-4-carbaldehyde (**1**) (0.01 mol) and 2-cyanoacetohydrazide (0.01 mol) in 1,4-dioxane (30 mL) was refluxed for 1 h. After cooling, the crystals formed were filtered, washed with water and recrystallized from ethanol (95%) to give compound (**2**).
- General procedure for the synthesis of 6-amino-1-((1,3-diphenyl-1H-pyrazole-4-yl)methyleneamino)-4-(4-methoxyphenyl)-2-oxo-1,2-dihydropyridine-3,5-dicarbonitriles (**4a–t**): A mixture containing 2-cyano-N-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)acetohydrazide (**2**) (0.01 mol), 2-(arylidene)malononitriles (**3a–t**) (0.01 mol) and catalytic amount of piperidine in ethanol (95%) (30 mL) was refluxed for 3 h. After cooling, the crystals formed were filtered, washed with water and recrystallized from aqueous DMF to give compounds **4a–t**.
- Hannan, P. C. *Vet. Res.* **2000**, *31*, 373.
- Sharma, P.; Rane, N.; Gurram, V. K. *Bioorg. Med. Chem. Lett.* **2004**, *14*, 4185.
- Sharma, D.; Narasimhan, B.; Kumar, P.; Judge, V.; Narang, R.; De Clercq, E.; Balzarini, J. *Eur. J. Med. Chem.* **2009**, *44*, 2347.
- Mosmann, T. *J. Immunol. Methods* **1983**, *65*, 55.